Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 2.72 g/t Au over 139.9 metres at Golden Summit (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenon Pharmaceuticals Inc XENE

Healthcare Biotechnology
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, the... see more

Recent & Breaking News (NDAQ:XENE)

Xenon Outlines Key Corporate Milestone Opportunities for 2025

GlobeNewswire 8 days ago

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 7, 2025

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

GlobeNewswire December 6, 2024

Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

GlobeNewswire November 25, 2024

Xenon to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2024

Xenon Reports Q3 2024 Financial Results and Business Update

GlobeNewswire November 12, 2024

Xenon to Report Q3 2024 Financial Results on November 12, 2024

GlobeNewswire November 5, 2024

Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference

GlobeNewswire October 2, 2024

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

GlobeNewswire September 9, 2024

Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer

GlobeNewswire August 12, 2024

Xenon Reports Q2 2024 Financial Results and Business Update

GlobeNewswire August 8, 2024

Xenon to Report Q2 2024 Financial Results on August 8, 2024

GlobeNewswire August 1, 2024

Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 5, 2024

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

GlobeNewswire May 28, 2024

Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 9, 2024

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024

GlobeNewswire May 8, 2024

Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 7, 2024

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

GlobeNewswire May 2, 2024

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

GlobeNewswire April 16, 2024

Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

GlobeNewswire April 10, 2024